+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Choroideremia Pipeline Analysis 2019 (H1)

  • PDF Icon

    Report

  • 81 Pages
  • May 2019
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 4801645
Choroideremia Pipeline Analysis report covers 5 drugs currently in different phases of development. Choroideremia is a rare inherited disorder characterized by progressive vision loss due to degeneration of the choriocapillaris, retinal pigment epithelium, and the photoreceptor of the eye. Symptoms of the disease are night-blindness, vision loss in mid-periphery and appearance of the blind spots and may lead to complete blindness. It is a genetic defect of X-chromosome thus mostly affect the males.

The report provides Choroideremia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.

Major industry players profiled as part of the report are 4D Molecular Therapeutics, Horama S.A., Nightstar Therapeutics, RegenXbio, and Spark Therapeutics.

Scope:
  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration

Table of Contents

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
  • Drug Name
  • Generic Name
  • Synonyms
  • Company
  • Collaborator
  • Route of administration
  • Target
  • Mechanism of Action
  • Technology
  • Molecule type
  • CAS Number
  • Weight
  • Chemical Formula
  • IUPAC name
  • ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. 4 d Molecular Therapeutics
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Biogen S.A.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.2.5. Recent Development
6.3. Nightstar Therapeutics
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.3.5. Recent Development
6.4. RegenXbio
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.4.5. Recent Development
6.5. Spark Therapeutics
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.5.5. Recent Development

Companies Mentioned

  • 4d Molecular Therapeutics
  • Biogen S.A.
  • Nightstar Therapeutics
  • RegenXbio
  • Spark Therapeutics